Toxicological screening detected opiates and tetrahydrocannabinol. The authors note that illicitly manufactured opioid preparations may contain toxic contaminants capable of causing severe local tissue injury, but a causal relationship between a specific illicit preparation and extensive necrotizing lesions is often difficult to establish because analytical confirmation is rarely available. Admission blood cultures and early wound cultures were negative. Local microbiological samples obtained after broad-spectrum antimicrobial therapy had begun later yielded multiple healthcare-associated organisms, including VIM-producing Pseudomonas aeruginosa and vancomycin-resistant Enterococcus faecium.

The investigators interpreted the later isolates as secondary wound colonization and/or infection rather than evidence that a resistant organism caused the original necrosis. The timing of sample collection and the initial antimicrobial exposure limit the conclusions that can be drawn from these cultures about when or how the resistant organisms were acquired. Despite empirical antimicrobial therapy, tissue necrosis progressed and required repeated surgical debridement. Histopathological examination showed necrosis of the skin and subcutaneous tissue with a suppurative inflammatory infiltrate.

The reported course included prolonged wound care, culture-directed antimicrobial therapy and reconstructive treatment. As a single-patient case report summarized from the article abstract, the study cannot establish comparative outcomes, population-level incidence or a causal link between any particular exposure, toxic adulterant or later multidrug-resistant organism and the lesions. It documents an unresolved initial etiology followed by resistant organisms interpreted by the authors as secondary healthcare-associated colonization and/or infection, while also illustrating the diagnostic difficulty of extensive necrotizing soft tissue injury in a patient with polysubstance use and recent trauma.

Subject of Research: A single-patient case report of necrotizing soft tissue injury followed by multidrug-resistant wound colonization and/or infection

Article Title: Severe necrotizing soft tissue injury with secondary multidrug-resistant wound colonization and infection in a patient with polysubstance use and suspected toxic adulterant exposure: a case report

Article References: Azzaddin, L., Giedzicz, K., Stawarz, W., Dytkowski, M., Jabłoński, R., & Hady, H. R. (2026). Severe necrotizing soft tissue injury with secondary multidrug-resistant wound colonization and infection in a patient with polysubstance use and suspected toxic adulterant exposure: a case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14506-w

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14506-w

Keywords: case report, necrotizing soft tissue injury, multidrug-resistant organisms, wound colonization, polysubstance use, healthcare-associated infection, surgical debridement, acute kidney injury, toxicological screening, Severe, necrotizing, soft

The study, published in BMC Infectious Diseases, analyzed clinical records from infants admitted to the hospital’s neonatal intensive care unit between May 2023 and February 2025. All of the patients were preterm, and the median age at which sepsis first appeared was just sixteen days, though the range stretched remarkably wide, from seven days to 223 days after birth. That timing matters. Late-onset sepsis, meaning infection that develops after the first seventy-two hours of life, is a leading cause of illness and death in preterm infants, and the usual suspects are well-known organisms such as coagulase-negative staphylococci. Bacillus cereus rarely tops the list of clinical suspicions, and that is precisely the problem the researchers set out to illuminate.

The clinical picture that emerged from the nineteen cases was strikingly non-specific, which helps explain why the organism is so easy to overlook. Every single infant, one hundred percent of the cohort, presented with poor responsiveness, a vague sign that overlaps with countless other conditions in fragile newborns. Fever was present in fourteen patients, or 73.9 percent, and apnea, the temporary cessation of breathing, occurred in twelve infants, accounting for 63.2 percent. None of these findings would immediately point a clinician toward Bacillus cereus. In fact, the study’s authors note that positive blood cultures for this organism are frequently dismissed as contamination, since Bacillus species are common environmental organisms that can inadvertently seed a culture bottle during sampling. Distinguishing true invasive infection from a stray contaminant requires clinical judgment, and the stakes of getting that call wrong are now considerably clearer.

One of the most consequential findings of the study concerned breathing. Among the sixteen infants who had not been receiving invasive mechanical ventilation before the onset of sepsis, ten, or 62.5 percent, required escalation to a higher level of respiratory support once the infection took hold. The researchers report this figure with a 95 percent confidence interval of 35.4 percent to 84.8 percent, a wide range that reflects the modest sample size but still signals a consistent pattern. In practical terms, a sudden deterioration in respiratory status in a preterm infant, manifesting as new or worsening apnea and increased oxygen requirements, may be one of the earliest and most reliable signals that sepsis is developing. For neonatal clinicians, the message is that a step up in respiratory support should trigger a careful search for infection, including blood cultures, rather than being attributed to the infant’s underlying prematurity alone.

The microbiology added its own sobering lessons. Every strain isolated in the cohort was resistant to penicillin and ampicillin, the beta-lactam antibiotics that form the backbone of empiric therapy for many neonatal infections. This resistance is a hallmark of Bacillus cereus, which produces beta-lactamase enzymes that dismantle penicillin-class drugs. The good news is that all strains remained susceptible to meropenem, vancomycin, and linezolid, giving clinicians effective options once the organism is identified. But the resistance pattern underscores a diagnostic trap: if Bacillus cereus is not considered and the infant is treated with ampicillin alone, the infection may continue to progress even as treatment appears to be under way. Timely identification of the organism and rational adjustment of the antimicrobial regimen are therefore not optional refinements but essential steps in managing these patients.

The most alarming dimension of the study concerns the central nervous system. Two of the nineteen infants, or 10.5 percent, developed purulent meningitis, the bacterial infection of the membranes surrounding the brain, and one of those cases progressed to a brain abscess, a localized collection of pus within brain tissue itself. The researchers provided a detailed account of this abscess case and then cast a wider net, searching the published literature for other reported cases of neonatal Bacillus cereus brain abscess. Combining their own patient with the literature yielded fifteen cases in total. Among those fifteen infants, five deaths were reported, a mortality rate of 33.3 percent. And the toll did not end with survival: some of the children who lived were left with neurological sequelae, lasting damage to brain function that can shape development for a lifetime.

The outcome of the Quanzhou abscess case illustrates both the gravity of the complication and the possibility of rescue through aggressive intervention. The infant survived after undergoing surgical drainage of the abscess combined with long-term antimicrobial therapy, a regimen that must be sustained for weeks to eradicate bacteria sequestered within an abscess cavity, where antibiotic penetration is poor and the blood-brain barrier complicates drug delivery. Yet survival came with a caveat. At twenty months of age, the child exhibited mild neuromotor developmental delay, a reminder that even successfully treated central nervous system infection in a preterm infant can leave subtle but meaningful traces on the developing brain. The developing nervous system of a premature infant is uniquely vulnerable, and inflammatory injury during critical windows of brain maturation can disrupt processes that unfold over months and years.

Overall mortality in the cohort was 5.3 percent, meaning one of the nineteen infants died, with a 95 percent confidence interval of 0.1 percent to 26.0 percent. That figure, while far lower than the mortality seen in the brain abscess literature, still represents a death toll from an organism that many clinicians would regard as a nuisance contaminant. The authors argue that their findings justify a more proactive diagnostic pathway. In their view, any preterm infant with a positive blood culture for Bacillus cereus should undergo lumbar puncture to examine the cerebrospinal fluid and cranial imaging as soon as possible, rather than waiting for neurological signs to appear. By the time seizures, bulging fontanelles, or other overt signs of central nervous system involvement emerge, an abscess may already be forming. Serial neuroimaging and long-term neurodevelopmental follow-up round out the recommended approach, ensuring that survivors are monitored for delays that may only become apparent as they grow.

Where does the bacterium come from in the first place? The study points to potential sources that are uncomfortably close to the infant’s bedside: contaminated environmental surfaces, medical equipment, and nutritional products, including breast milk and formula. Bacillus cereus is a spore-forming organism, and its spores are notoriously resistant to heat, drying, and disinfectants, allowing it to persist on surfaces and in equipment long after cleaning. This resilience is what makes the bacterium such a formidable opportunist in hospital settings. The authors emphasize that prevention rests on disciplined fundamentals: strict hand hygiene among staff and caregivers, regular and thorough disinfection of the environment and medical devices, and careful handling of breast milk and formula to prevent bacterial growth. These measures are neither glamorous nor technologically novel, but they target the routes by which spores travel from the environment into the bloodstream of an infant whose immune defenses are still under construction.

The significance of this study lies less in any single statistic than in the cumulative picture it paints. Bacillus cereus sepsis in preterm infants is rare enough that most evidence has previously been limited to isolated case reports or small series, leaving clinicians without a clear sense of the typical presentation, the likely course, or the full range of complications. By assembling nineteen cases from a single center and pairing them with a systematic review of the brain abscess literature, the Quanzhou team has transformed a scattered collection of anecdotes into a coherent clinical profile: a non-specific onset marked by poor responsiveness, fever, apnea, and escalating respiratory support; universal beta-lactam resistance demanding prompt antimicrobial adjustment; and a real, quantifiable risk of meningitis and brain abscess with lasting developmental consequences. For the neonatologists and infection-control teams who staff the world’s intensive care nurseries, the study is a call to take this soil-dwelling organism seriously, to investigate positive cultures rather than dismissing them, and to look beyond the bloodstream toward the brain before it is too late.

Subject of Research: Invasive Bacillus cereus sepsis and neurological complications in hospitalized preterm infants

Article Title: Invasive Bacillus cereus infection in hospitalized preterm infants: clinical characteristics, outcomes, and neurological complications from a single-center retrospective case series

Article References: Xue’e, Z., Zhiyong, L., Xialin, Y., Jiangbin, C., Jingyang, Z., Tianfeng, C., Ruiquan, W., Lianqiang, W., Weifeng, Z., Jinglin, X., Dongmei, C., & Hongyuan, Y. (2026). Invasive Bacillus cereus infection in hospitalized preterm infants: clinical characteristics, outcomes, and neurological complications from a single-center retrospective case series. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14504-y

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14504-y

Keywords: Bacillus cereus, preterm infants, neonatal sepsis, brain abscess, meningitis, neonatal intensive care, antimicrobial resistance, meropenem, vancomycin, neurodevelopmental delay, healthcare-associated infection, infection control

Difficult-to-treat resistance is a recently formalized category, and its technical definition matters for understanding why these infections are so alarming. According to the criteria widely adopted from United States Centers for Disease Control and Prevention guidance and reflected in the Clinical and Laboratory Standards Institute’s M100 performance standards, a Gram-negative pathogen is labeled DTR when it is nonsusceptible to all agents in the standard first-line categories: all penicillins and beta-lactam and beta-lactamase inhibitor combinations, all cephalosporins, all carbapenems, the fluoroquinolones, and at least one of the aminoglycosides. In practical terms, a DTR Klebsiella isolate leaves clinicians with almost nothing from the traditional antibiotic armamentarium, forcing reliance on newer beta-lactam and beta-lactamase inhibitor combinations, tetracycline derivatives such as eravacycline, or the last-resort polymyxin colistin, each of which carries its own limitations in efficacy, toxicity, and availability.

The biology of Klebsiella pneumoniae makes it a particularly formidable opponent in cancer care. The organism is a Gram-negative bacillus equipped with an outer membrane rich in porins and a polysaccharide capsule that shields it from complement-mediated killing and phagocytosis. Resistance in DTR strains typically arises through the acquisition of beta-lactamase genes, including extended-spectrum beta-lactamases and carbapenemases such as those of the KPC, NDM, OXA-48-like, and VIM families, which hydrolyze the drugs that would otherwise destroy the cell wall. These genes frequently sit on plasmids that can transfer horizontally between bacterial species, meaning that resistance can spread within a hospital’s microbial ecosystem even when individual bacterial cells do not. For patients whose immune defenses are dismantled by chemotherapy, neutropenia, invasive devices, and repeated hospitalizations, such an organism finds an environment with few natural barriers.

Cancer patients represent a uniquely vulnerable population for these infections, a point the Varanasi team emphasizes by situating their investigation squarely in supportive care rather than pure microbiology. Intensive chemotherapy regimens produce prolonged periods of severe neutropenia, during which the body’s primary cellular defense against bacteria is largely absent. Mucosal barriers lining the gastrointestinal tract are damaged by cytotoxic drugs, allowing intestinal colonizing bacteria to translocate into the bloodstream. Central venous catheters, urinary catheters, and ventilatory support provide direct conduits for microorganisms to bypass skin defenses. Prolonged and repeated hospital admissions increase exposure to the hospital flora, and broad-spectrum prophylactic or empiric antibiotics, often necessary in this population, apply the selective pressure that favors resistant strains over susceptible competitors. The result is a patient population in which multidrug-resistant Gram-negative infections are both more common and more lethal than in the general hospitalized population.

Recent evidence underscores how grim the prognosis has become even in high-resource settings. A retrospective cohort study published in The Lancet Infectious Diseases in 2026 by Walker and colleagues examined survival trends among patients with difficult-to-treat, antibiotic-resistant Gram-negative infections in the United States during the era of next-generation antibiotics, and its inclusion in the Varanasi paper’s reference list signals the authors’ awareness that mortality in this syndrome remains substantial despite the arrival of new drugs. Severe infections caused by difficult-to-treat Gram-negative bacteria, as reviewed by Dettori, Bassetti, and colleagues in Current Opinion in Critical Care, frequently present as bloodstream infections, ventilator-associated pneumonia, or complicated intra-abdominal infections, and delays in appropriate empiric therapy are consistently associated with worse outcomes. In oncology patients, the combination of host immunosuppression and near-total antibiotic resistance creates a clinical scenario in which every hour of ineffective therapy matters.

Accurate susceptibility testing is therefore not a laboratory formality but a life-or-death variable, and this technical dimension occupies a significant place in the Varanasi group’s broader research program. Colistin, the polymyxin antibiotic often reserved for DTR organisms, is notoriously difficult to test reliably. Its large, amphipathic molecule aggregates in aqueous solution and does not diffuse well in agar, which is why traditional disk diffusion performs poorly. The reference standard, broth microdilution, is technically demanding and impractical for many laboratories in resource-limited settings. In response, the Clinical and Laboratory Standards Institute has endorsed broth disk elution as an alternative, a method in which colistin is eluted from a disk into broth before inoculation. A 2025 study by Chandankhede, Karyakarte, and colleagues compared broth disk elution with broth microdilution for carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, and a prospective study by CV, Priya, Chauhan, and Dhingra specifically evaluated the diagnostic performance of the two methods for carbapenem-resistant Gram-negative bacilli from cancer patients in India. These methodological comparisons matter because an erroneous report of susceptibility, or of resistance, directly changes whether a critically ill cancer patient receives an effective regimen.

The Varanasi investigation itself was structured as a formal healthcare-associated outbreak investigation, a discipline with well-established epidemiological methods. Outbreak investigation in a hospital setting begins with case ascertainment and the construction of a case definition, followed by descriptive epidemiology that maps cases by person, place, and time to identify patterns of transmission. When multiple patients harbor isolates with identical or closely related resistance profiles, the possibility of a common source or of clonal spread via healthcare workers’ hands, contaminated equipment, or the shared hospital environment must be systematically evaluated. The authors acknowledge support for the infection prevention and control assessment component of their investigation from Professor Purva Mathur of the Jai Prakash Narayan Apex Trauma Centre at AIIMS New Delhi and from Dr. A. S. Valan, a public health specialist at the Centers for Disease Control and Prevention India Country Office in New Delhi, indicating that the assessment was aligned with international standards, including the World Health Organization’s 2023 assessment tool on infection prevention and control minimum requirements for tertiary health care facilities.

That WHO tool provides a structured framework for evaluating whether a tertiary facility meets minimum IPC standards across core components such as governance and dedicated IPC staffing, guidelines and protocols, surveillance of healthcare-associated infections, microbiology laboratory capacity, environmental cleaning and sterilization, and the built environment and equipment. In cancer hospitals, the stakes of each component are amplified. High-touch surfaces around immunosuppressed patients, shared bathroom facilities, water systems, and medical devices all represent potential reservoirs for Klebsiella, which can survive on inanimate surfaces for extended periods. Hand hygiene compliance, cohorting of colonized or infected patients, rigorous terminal cleaning of rooms, and antimicrobial stewardship programs that limit unnecessary broad-spectrum exposure form the interlocking defenses that keep resistant organisms contained. An outbreak of DTR Klebsiella in such a setting is therefore as much a systems failure as a microbiological event, and the investigation’s value lies in identifying which links in the chain of transmission broke down.

The broader significance of the study extends well beyond a single institution in northern India. Carbapenem-resistant Klebsiella pneumoniae has been designated a critical-priority pathogen on the World Health Organization’s bacterial priority pathogens list, and the global spread of carbapenemase genes, particularly those encoding NDM-type enzymes that are endemic across the Indian subcontinent, means that cancer centers everywhere face converging threats. The Varanasi paper’s title phrase, beyond the tumor, captures a conceptual shift that supportive oncology has been undergoing: survival in cancer medicine increasingly depends not only on the effectiveness of antineoplastic therapy but on the invisible war being waged against resistant bacteria in the wards, laboratories, and plumbing of the hospitals where treatment occurs. As next-generation antibiotics arrive, their durability will depend on how well healthcare systems prevent the transmission events that this outbreak investigation documents, because every new drug deployed against a resistant cluster applies the selective pressure that can eventually render it ineffective too.

For clinicians and hospital administrators, the message of the study is operational as much as scientific. Rapid detection of DTR phenotypes through reliable susceptibility methods, prompt notification of infection control teams when clusters emerge, disciplined application of contact precautions, and sustained investment in laboratory capacity and IPC infrastructure are the concrete measures that determine whether a cluster remains a cluster or becomes a sustained institutional epidemic. For patients and families, the study is a reminder that modern cancer care is a team effort in which microbiologists, infection preventionists, and oncologists share responsibility for outcomes, and that the fight against antimicrobial resistance is inseparable from the fight against cancer itself.

Subject of Research: Healthcare-associated outbreak of difficult-to-treat Klebsiella pneumoniae infection among cancer patients

Article Title: Beyond the tumor: cluster of difficult-to-treat (DTR) Klebsiella pneumoniae infection in cancer patients—healthcare-associated outbreak investigations

Article References: Bajpai, V., Mishra, A., John, N., Sarode, R., Chaurasia, A., Bharti, S., Kapoor, A., & Mishra, B. K. (2026). Beyond the tumor: cluster of difficult-to-treat (DTR) Klebsiella pneumoniae infection in cancer patients—healthcare-associated outbreak investigations. Supportive Care in Cancer, 34(10), Article 1055. https://doi.org/10.1007/s00520-026-11277-7

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11277-7

Keywords: Klebsiella pneumoniae, difficult-to-treat resistance, antimicrobial resistance, cancer patients, healthcare-associated infection, outbreak investigation, infection prevention and control, carbapenem-resistant Enterobacterales, colistin susceptibility testing, supportive oncology, immunocompromised hosts, hospital epidemiology

Candidozyma auris has earned a reputation as one of the most concerning healthcare-associated fungal pathogens of the modern era. Unlike many of its fungal relatives, it persists stubbornly in the hospital environment, colonizes surfaces and medical equipment, spreads between patients in healthcare facilities, and frequently displays resistance to the antifungal drugs clinicians rely upon most. First recognized as a human pathogen less than two decades ago, it has since been reported on multiple continents, triggering outbreaks in intensive care units and prompting public health agencies to classify it as a serious global health threat. Its ability to survive routine disinfection and to be misidentified by conventional laboratory methods has made containment exceptionally difficult, and each new clinical dataset contributes valuable intelligence about how the organism behaves in actual patient care.

The Turkish research team set out to answer a question that has divided the field: does C. auris candidemia actually kill more patients than candidemia caused by other Candida species, or does it merely appear more lethal because it disproportionately infects patients who are already gravely ill? To address this, the investigators conducted a single-center retrospective cohort study, identifying every adult patient with candidemia seen at their institution and classifying infections by species. Identification was performed using MALDI-TOF mass spectrometry, a rapid proteomic technique that has become the gold standard for distinguishing C. auris from look-alike yeasts that older biochemical panels frequently confuse with it. Accurate speciation matters enormously here, because misidentification has historically hampered both surveillance and appropriate treatment.

The clinical profiles of the two patient groups differed in telling ways. Patients with C. auris candidemia had spent significantly longer in the hospital before their bloodstream infection developed, a pattern consistent with a healthcare-associated pathogen that colonizes patients during extended stays. They also more frequently had central venous catheters, the indwelling lines that provide fungi with a direct portal into the bloodstream, and greater exposure to corticosteroids, which suppress immune defenses. These exposures are classic risk factors for invasive candidiasis in general, but their heightened frequency in the C. auris group underscores how thoroughly this organism is woven into the fabric of modern intensive medical care. The findings reinforce the picture of C. auris as an opportunist that exploits the very devices and drugs that keep critically ill patients alive.

When the researchers examined crude outcomes, the headline number was striking in its symmetry: 30-day all-cause mortality was 62.3 percent among patients with C. auris candidemia and 62.5 percent among those with non-auris Candida infections, a difference of essentially zero. On the surface, this suggests the emerging pathogen is no deadlier than its established cousins. But crude comparisons in observational data can be deeply misleading, and the investigators knew that the patients harboring C. auris arrived at their infections with a different constellation of vulnerabilities. To disentangle the effect of the organism itself from the effect of patient characteristics, they turned to more sophisticated statistical machinery.

The team employed a multivariable Firth-penalized logistic regression model, a technique designed to produce more stable estimates when outcomes are imbalanced or sample sizes are modest, and they handled missing data through multiple imputation. The model was constructed with clinical input to ensure that the variables adjusted for reflected genuine medical knowledge rather than statistical convenience. After adjustment, C. auris candidemia was associated with higher estimated odds of 30-day mortality, with an adjusted odds ratio of 1.967, meaning the odds of death were nearly doubled relative to non-auris candidemia. However, the 95 percent confidence interval ranged from 0.954 to 4.055 and included the null value of one, with a p value of 0.067, meaning the association fell just short of conventional statistical significance.

To translate the regression results into more intuitive risk terms, the researchers used g-computation to estimate standardized marginal mortality risks. Under this approach, the adjusted 30-day mortality was estimated at 69.7 percent for C. auris candidemia compared with 59.3 percent for non-auris Candida candidemia, corresponding to an adjusted risk difference of 10.4 percentage points, with a confidence interval spanning from minus 0.2 to plus 21.3 points. In other words, once patient severity was accounted for, the data hinted that C. auris infections carry a genuinely elevated mortality burden, potentially adding roughly ten deaths per hundred patients, but the uncertainty around that estimate means the true effect could range from negligible to substantial. The authors are explicit that these findings should be interpreted as associative rather than causal, and that larger prospective multicenter studies across diverse healthcare settings are needed to confirm them.

Beyond the comparison between species, the study identified the factors that independently predicted death within 30 days across the entire cohort. Older age, higher scores on the Sequential Organ Failure Assessment, or SOFA, scale, the presence of septic shock, corticosteroid use, and hemodialysis were all associated with higher adjusted odds of mortality. These determinants are familiar from the broader candidemia literature: they reflect the reality that bloodstream fungal infections are most lethal in patients whose organs are already failing and whose immune systems have been blunted by illness or medication. The consistency of these predictors with prior research lends credibility to the study’s methodology and suggests the dataset behaves as expected, strengthening confidence in the species-specific comparisons.

The antifungal susceptibility findings carry important practical implications for treatment. Among C. auris isolates, echinocandin non-wild-type phenotypes were uncommon, which is welcome news because echinocandins are the recommended first-line therapy for invasive candidiasis and are often the drug class of choice against C. auris. However, elevated minimum inhibitory concentrations for amphotericin B were observed in approximately one-third of tested isolates, a troubling signal for an older but still-used antifungal that clinicians may reach for when first-line options fail or are unavailable. Meanwhile, resistance to fluconazole was frequent among tested Candida parapsilosis isolates, a reminder that antifungal resistance is not confined to the emerging pathogen and that susceptibility testing remains essential for guiding therapy across all Candida species. Susceptibility results were interpreted using applicable EUCAST clinical breakpoints or epidemiological cut-off values, and where no interpretive criteria existed, results were reported descriptively, reflecting the ongoing challenge that interpretive standards for some antifungal-organism combinations are still evolving.

The study’s conclusions are measured but consequential. C. auris candidemia, the authors report, is characterized by a distinct profile of healthcare-associated exposures and a distinct antifungal susceptibility pattern, and while crude mortality appears similar to other candidemia, adjusted estimates point toward higher mortality that remains statistically imprecise. For clinicians, the message is twofold: patients colonized or infected with C. auris deserve vigilant attention to modifiable risk factors such as catheter management and careful stewardship of corticosteroids, and treatment decisions should be anchored in susceptibility data rather than assumptions. For public health officials, the findings add to the accumulating evidence that C. auris is not simply another Candida species but a pathogen with its own epidemiology, its own resistance landscape, and potentially its own mortality penalty. As the global footprint of this fungus continues to expand, studies like this one, grounded in real-world clinical data and rigorous statistical adjustment, will be essential for calibrating the response. The research received no specific funding, was approved by the Etlik City Hospital clinical research ethics committee, and was conducted in accordance with the Declaration of Helsinki, with the requirement for informed consent waived given its retrospective design.

Subject of Research: Comparison of clinical characteristics, antifungal susceptibility, and 30-day mortality in Candidozyma auris versus non-auris Candida candidemia

Article Title: Clinical characteristics, treatment strategies, and factors associated with 30-day mortality in Candidozyma auris versus non-auris Candida candidemia: a retrospective cohort study

Article References: Kuzi, S., Çiçek Şentürk, G., Kul, G., Haykır, A., Yılmaz, N., Korkmaz, N., Bulut, D., Aslan, M., Yapar Toros, G., Şencan, İ., & Tütüncü, E. E. (2026). Clinical characteristics, treatment strategies, and factors associated with 30-day mortality in Candidozyma auris versus non-auris Candida candidemia: a retrospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14401-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14401-4

Keywords: Candidozyma auris, candidemia, antifungal resistance, 30-day mortality, bloodstream infection, echinocandins, amphotericin B, fluconazole resistance, septic shock, healthcare-associated infection, MALDI-TOF, risk factors